BioSpace News Archive

BioInvent International AB’s partner Oxurion NV has reported topline data from a Phase lla study evaluating THR-317, a humanized antibody against placental growth factor, in combination with anti-VEGF, an anti-vascular endothelial growth factor antibody, for the treatment of Diabetic Macular Edema.

Becomes the only clinical logistics provider with fully integrated services

The global anti-CD20 monoclonal antibodies is expected to post a CAGR of over 9% during the period 2019-2023, according to the latest market research report by Technavio.

Melmark, Inc. has announced the promotion of Tom Crofcheck, CPA to Vice President and Chief Financial Officer (CFO).

Organigram’s common shares will commence trading on the TSX at the opening on Thursday August 22, 2019, continuing to trade under the symbol OGI.

Leading respiratory medical device company Adherium has unveiled its new strategic data-based initiative with Summatix Pty Ltd, with the objective of enabling clinicians globally to enhance their care of patients with asthma and chronic obstructive pulmonary disease.

Avivagen Inc. is pleased to announce that it has received approval for OxC-beta™ Livestock in Mexico.

The global Interleukin inhibitors market 2019-2023 is expected to post a CAGR of more than 13% during the period 2019-2023, according to the latest market research report by Technavio.

Lannett Company, Inc. announced that it will report financial results for its fiscal 2019 fourth quarter and full year on Tuesday, August 27, 2019, after the market closes.

Genesis Innovation Group and their cultivate Capital Fund II, LP, a fund focused on investments into early stage healthcare companies with innovative technologies, announced their investment into Grand Rapids, MI based Genesis Software Innovations, “GSI,” a company developing unique software solutions focused initially in the orthopedic space.